Che materia stai cercando?

Anteprima

ESTRATTO DOCUMENTO

Humoral immunity, inflammation and cancer Tan and Coussens 213

develop epithelial cancers in the gastrointestinal tract that are not only essential for resolving acute tissue damage

where prominent plasma cell hyperplasia was evident but also essential for promoting tumor development in

adjacent to developing duodenal polyps. Mice harboring initiated tissues.

germline mutations in Smad4 did not exhibit any of these

FcgR and C5a are key regulators of

]. Smad4-deficient T cells

same characteristics [40 IC-mediated inflammation

become skewed in their cytokine profile and prominently Inflammatory responses to ICs have been extensively

express several Th2-type cytokines including IL-4, -5, -6 studied in transgenic mouse models of various auto-

and -13. These pro-tumor mediators also enhance plasma immune diseases [47]. Mechanisms by which ICs initiate

cell differentiation, thus demonstrating that altering local inflammation are still not fully understood; however,

balances of important cytokine pathways, by differential receptors for the Fc portion of IgG (FcgRs, especially

regulation of either HI or CMI, profoundly influences FcgRIII) and complement factors (particularly C5a ana-

malignant risk and argues that perturbing these balances phylatoxin) are recognized as co-dominant effectors in the

to favor anti-tumor immunity represents a powerful anti- process [47]. Considering the fact that tissues damaged by

cancer approach. autoimmune dysfunction and by cancer have similar

ICs have long been suspected as initiators of inflamma- characteristics (e.g. chronic innate immune cell infiltra-

tory cascades associated with tissue destruction in auto- tion, tissue remodeling, angiogenesis, altered cell survival

immune diseases but underlying molecular mechanisms pathways) [48], it seems probable that similar IC effector

have been elusive [41]. Recent investigations of these pathways are involved in pathogenesis of both diseases.

mechanisms using an experimental mouse model of air-

way remodeling following Mycoplasma pulmonis infection Expressed on most leucocytes, FcgRs are classified into

have demonstrated that peripheral B cell responses and four groups (FcgRI/CD64, FcgRII/CD32, FcgRIII/

local Ig-IC deposition are the critical triggers for recruit- CD16 and recently identified FcgRIV) according to their

ing innate leucocytes into infected airways, that then distinct affinities for IgG, cell distributions and functions.

activate pro-angiogenic and tissue remodeling pathways FcgRI and FcgRIII, predominantly FcgRIII, mediate

necessary for resolving infection [42]. We have reported immune cell activation via their FcR chain that contains

g

complimentary findings using a transgenic mouse model an intracellular tyrosine-based activating motif (ITAM).

]. Here, oncogenes

of squamous carcinogenesis [43,44 Activating signals mediated by ITAM trigger oxidative

from human papillomavirus type 16 (HPV16) are bursts, cytokine release and phagocytosis by macro-

expressed in skin keratinocytes under direction of a phages, antibody-dependent cell-mediated cytotoxicity

human keratin 14 (K14) promoter/enhancer and initiate (ADCC) by natural killer (NK) cells, and degranulation of

multi-stage development of squamous cell carcinomas mast cells [41]. In contrast, engagement of FcgRIIB that

,45]. In HPV16 trans-

(SCCs) in skin and cervix [43,44 instead contains immune tyrosine-based inhibitory motifs

genic mice, combined B- and T-lymphocyte-deficiency (ITIM) inhibits these same inflammatory responses [41].

eliminated IC deposition in premalignant skin and atte- These two opposing regulatory pathways coexist on

nuated innate immune cell infiltrations, resulting in innate immune cells and thus, in part, determine the

diminished tissue remodeling activity, failure to activate magnitude of IC-mediated inflammatory responses.

angiogenic vasculature, retention of terminal differen- Indeed, the ratio of activating to inhibitory FcgR is

tiation programs in skin keratinocytes and a 43% reduction low in ’normal’ homeostatic tissues, and by contrast is

]. Adoptive transfer of B-

in overall SCC incidence [44 highly increased in inflamed microenvironments [47].

lymphocytes or serum isolated from HPV16 mice (but not

from wild-type naı̈ve mice) into B- and T-lymphocyte- Receptors for the Fc portion of IgG, FcgRs play a central

deficient/HPV16 mice restored IC deposition, chronic role in regulating immune responses following interaction

innate immune cell infiltration in pre-malignant skin with ICs [41]. It was recently demonstrated that presence

]. These

and reinstated parameters for full malignancy [44 or absence of sialic acid at the terminus of the core glycan in

].

data indicate that B-lymphocyte-derived factors, possibly the Fc region of IgG regulates immune response [49

Ig, are essential for establishing chronic inflammatory Sialylation of the Fc region of IgG reduces binding affi-

nities towards FcgRs thereby inhibiting pro-inflammatory

pathways that potentiate cancer development. In support activities of IgG, whereas reduction of sialylation, upon

of this concept, anti-tumor antibodies are known to antigen challenge, switches the immune response pathway

enhance outgrowth and invasion of murine and human from anti-inflammatory to pro-inflammatory via differen-

tumor-cell xenografts through recruitment and activation ]. Regu-

tial engagement with FcgRs on effector cells [49

of granulocytes and macrophages [33], which are important latory functions of FcgRs have been studied using

sources of vascular endothelial growth factor (VEGF) [46] genetically engineered animal models. Mice deficient in

that possesses pro-angiogenic bioactivities. Thus, serum the FcR chain or activating type FcgRs are resistant to a

proteins (presumably antibodies) produced by B-lympho- g

wide range of IC-mediated hypersensitive reactions, such

cytes locally or peripherally, at least in some scenarios, are as vasculitis, glomerulonephritis and skin Arthus reaction

crucial factors that initiate chronic inflammatory programs,

www.sciencedirect.com Current Opinion in Immunology 2007, 19:209–216

214 Tumour immunology

[41]. Conversely, mice deficient in FcgRIIB exhibit initiate significant pro-tumor effects on developing neo-

enhanced IC-mediated inflammatory responses [41]. plasms. We propose that bolstering anti-tumor cell-

Although these elegant genetic studies demonstrate func- mediated immune responses, in combination with neutra-

tional importance of FcgRs in IC-mediated inflammation lizing potent pro-tumor humoral immune responses with

and autoimmune diseases, little is known about their role in efficacious immuno-therapeutics, would effectively direct

tumor development. tumor suppression while establishing an immune environ-

ment favoring therapeutic responses to conventional anti-

Complement activation is a central event during innate tumor modalities. Certainly, further studies are needed to

immune defence following pathogenic tissue assault. determine the universality of this approach and specifically

Three different pathways of complement activation have which types of human cancers would be amenable to such

been identified, namely classical, alternative and lectin therapy. Nonetheless, a dedicated attempt to reveal the

pathways. Foreign antigens and ICs activate complement molecular and cellular mechanisms linking HI, inflam-

cascades resulting in formation of lytic membrane attack mation and cancer will also provide important insights into

complexes and formation and liberation of anaphylatox- viable therapeutic targets for anti-cancer therapy.

ins; for example, C3a and C5a, potent pro-inflammatory Acknowledgements

factors that induce recruitment and activation of leuko- We acknowledge all the scientists who made contributions to the areas of

cytes. Deposition of complement proteins is a common research reviewed here that were not cited due to space constraints. The

occurrence at sites of inflammation. Studies utilizing authors were supported by grants from the National Institutes of Health

complement depleted mice and C3- or C5-deficient mice (CA72006, CA94168, CA098075), Sandler Program in Basic Sciences,

National Technology Center for Networks and Pathways (U54 RR020843)

have identified their crucial roles in regulating disease and a Department of Defense Era of Hope Scholar Award (BC051640).

pathogenesis [50,51]. We previously reported abundant

deposition of C3 in neoplastic skin of HPV16 mice; but References and recommended reading

found that C3-deficiency was without functional con- Papers of particular interest, published within the annual period of

review, have been highlighted as:

sequence, indicating that if Ig-ICs enhance premalignant

progression, they most likely contribute via regulation of of special interest

of outstanding interest

either FcgR or through C5a [52]. 1. de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the

C5a is a proteolytic fragment of C5 generated by the high- immune system during cancer development. Nat Rev Cancer

affinity C5 convertase, C3b complexed with C4b and C2a. 2006, 6:24-37.

Of note, complement-independent enzymes, such as 2. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized

inflammation in the initiation and promotion of malignant

thrombin, neutrophil elastase and a macrophage serine disease. Cancer Cell 2005, 7:211-217.

protease, have C5 convertase activity and therefore gen- 3. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002,

] (Figure 1).

erate C5a in a C3-independent manner [53 420:860-867.

C5a induces chemotaxis of macrophages, granulocytes, 4. Dalgleish AG, O’Byrne KJ: Chronic immune activation and

mast cells, dendritic cells and B-lymphocytes, and modu- inflammation in the pathogenesis of AIDS and cancer.

Adv Cancer Res 2002, 84:231-276.

lates their function through differential regulation of

]. The

activating FcgRs versus inhibitory FcgRs [54 5. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S:

Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs

initial contact between ICs and pulmonary alveolar as a parameter of immunological dysfunction in patients of

macrophages results in complement-independent C5a superficial transitional cell carcinoma of bladder. Cancer

Immunol Immunother 2006, 55:734-743.

production that causes decreased levels of inhibitory 6. Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe K,

FcgRIIB, increased levels of activating FcgRIII, and Suzuki S, Endoh Y, Takita K, Sekikawa K, Takenoshita S et al.:

highly induced FcgR-mediated cytokine production Effects of PSK on T and dendritic cells differentiation in gastric

or colorectal cancer patients. Anticancer Res 2005, 25:443-449.

] (Figure 1). Whether C5a-dependent modulation

[54

of FcgRs is a common mechanism operative in IC inflam- 7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B,

Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al.:

mation has yet to be determined. Nevertheless, a cellular Type, density, and location of immune cells within human

pathway of C5a production is evident in cultured macro- colorectal tumors predict clinical outcome. Science 2006,

313:1960-1964.

phages induced by antibody complex ligation to activat- Type, density and location of adaptive immune cell infiltrates in tumor

ing FcgR, indicating a complex regulatory network of samples were shown to be a better predictor of patient survival than

current histopathological staging of colorectal cancers.

multiple interactions between FcgR and C5a/C5aR [47].

Considering that autoimmune diseases and cancer have 8. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC:

Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes

common characteristics such as pronounced HI and IC in human cervical cancer. J Immunol 2001, 167:2972-2978.

deposition, FcgR and C5a/C5aR are likely to play a role in 9. Brandtzaeg P, Carlsen HS, Halstensen TS: The B-cell system

cancer-associated inflammation. in inflammatory bowel disease. Adv Exp Med Biol 2006,

579:149-167.

Conclusions 10. Ilavska S, Jahnova E, Tulinska J, Horvathova M, Dusinska M,

Wsolova L, Kyrtopoulos SA, Fuortes L: Immunological

Both clinical data and experimental animal studies monitoring in workers occupationally exposed to asbestos.

indicate that sustained humoral immune responses Toxicology 2005, 206:299-308.

Current Opinion in Immunology 2007, 19:209–216 www.sciencedirect.com

Humoral immunity, inflammation and cancer Tan and Coussens 215

11. Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, 29. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU,

Tra WM, Kleinjan A, Kwekkeboom J, van Vliet AH, Siersema PD: Nechustan H, Challita-Eid PM, Segal BM, Yi KH et al.: Increased

Barrett’s oesophagus is characterized by a predominantly rejection of primary tumors in mice lacking B cells: inhibition

humoral inflammatory response. J Pathol 2005, 207:269-276. of anti-tumor CTL and TH1 cytokine responses by B cells.

When reflux esophagitis progresses to Barrett’s esophagus, inflamma- Int J Cancer 2005, 117:574-586.

tory infiltration of Th1 effector cells is largely replaced by infiltration of Th2 B cell-deficient mice have higher resistance to several histologically

effector cells, suggesting that pronounced humoral immunity might diverse primary syngeneic tumors. The authors demonstrated that B

contribute to the increased risk for malignancy. cells suppress anti-tumor immunity by inhibiting Th1 and CTL response

in an antibody-independent manner.

12. Sakaguchi E, Kayano K, Segawa M, Aoyagi M, Sakaida I,

Okita K: [Th1/Th2 imbalance in HCV-related liver cirrhosis]. 30. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y:

Nippon Rinsho 2001, 59:1259-1263. Cancer and autoimmunity: autoimmune and rheumatic

features in patients with malignancies. Ann Rheum Dis 2001,

13. Barcelo B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, 60:433-441.

Agusti AG: Intracellular cytokine profile of T lymphocytes in

patients with chronic obstructive pulmonary disease. 31. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M,

Clin Exp Immunol 2006, 145:474-479. Miroglu C: Association of positive serum anti-p53 antibodies

with poor prognosis in bladder cancer patients. Int J Urol 2004,

14. Bernatsky S, Ramsey-Goldman R, Clarke A: Malignancy and 11:1070-1077.

autoimmunity. Curr Opin Rheumatol 2006, 18:129-134. 32. Schreiber H, Wu TH, Nachman J, Rowley DA: Immunological

15. Martin F, Chan AC: B cell immunobiology in disease: evolving enhancement of primary tumor development and its

concepts from the clinic. Annu Rev Immunol 2006, 24:467-496. prevention. Semin Cancer Biol 2000, 10:351-357.

16. Edwards JC, Cambridge G: B-cell targeting in rheumatoid 33. Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB: Promotion

arthritis and other autoimmune diseases. Nat Rev Immunol of tumor invasion by cooperation of granulocytes and

2006, 6:394-403. macrophages activated by anti-tumor antibodies.

Neoplasia 1999, 1:453-460.

17. Silverman GJ: Therapeutic B cell depletion and regeneration in

rheumatoid arthritis: emerging patterns and paradigms. 34. Aziz M, Das TK, Rattan A: Role of circulating immune

Arthritis Rheum 2006, 54:2356-2367. complexes in prognostic evaluation and management of

genitourinary cancer patients. Indian J Cancer 1997,

18. Gokbuget N, Hoelzer D: Novel antibody-based therapy for acute 34:111-120.

lymphoblastic leukaemia. Best Pract Res Clin Haematol 2006,

19:701-713. 35. Das TK, Aziz M, Rattan A, Sherwani R: Prognostic significance of

circulating immune complexes in malignant tumours of head

19. Leandro MJ, Isenberg DA: Rheumatic diseases and and neck. J Indian Med Assoc 1995, 93:3-7.

malignancy–is there an association? Scand J Rheumatol 2001,

30:185-188. 36. Dass TK, Aziz M, Rattan A, Tyagi SP: Clinical utility and

monitoring of breast cancer by circulating immune

20. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, complexes. Indian J Pathol Microbiol 1992, 35:298-307.

Feng L, Sampsel JW: B lymphocyte pathology in human

colorectal cancer. Experimental and clinical therapeutic 37. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD,

effects of partial B cell depletion. Cancer Immunol Immunother McDonald DM: Effect of inhibition of vascular endothelial

2000, 48:541-549. growth factor signaling on distribution of extravasated

antibodies in tumors. Cancer Res 2006, 66:1434-1445.

21. Qin Z, Blankenstein T: CD4+ T cell–mediated tumor rejection

involves inhibition of angiogenesis that is dependent on IFN 38. Rowley DA, Stach RM: B lymphocytes secreting IgG linked to

gamma receptor expression by nonhematopoietic cells. latent transforming growth factor-beta prevent primary

Immunity 2000, 12:677-686. cytolytic T lymphocyte responses. Int Immunol 1998, 10:355-363.

22. Sakamoto T, Saito H, Tatebe S, Tsujitani S, Ozaki M, Ito H, 39. Bierie B, Moses HL: Tumour microenvironment: TGFbeta: the

Ikeguchi M: Interleukin-10 expression significantly correlates molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006,

with minor CD8+ T-cell infiltration and high microvessel 6:506-520.

density in patients with gastric cancer. Int J Cancer 2006,

118:1909-1914. 40. Kim BG, Li C, Qiao W, Mamura M, Kasperczak B, Anver M,

Increased IL-10 expression was observed in patients with gastric cancer, Wolfraim L, Hong S, Mushinski E, Potter M et al.: Smad4

+

which closely correlated with tumor angiogenesis, attenuated CD8 T cell signalling in T cells is required for suppression of

infiltration and a poor prognosis. gastrointestinal cancer. Nature 2006, 441:1015-1019.

+

Mice harboring genetic deficiency of Smad4 in CD4 T cells spontaneously

23. Rose-John S, Scheller J, Elson G, Jones SA: Interleukin-6 develop epithelial cancers in the gastrointestinal tract where prominent

biology is coordinated by membrane-bound and soluble plasma cell hyperplasia was evident adjacent to developing duodenal

receptors: role in inflammation and cancer. J Leukoc Biol 2006, polyps. Smad4-deficient T cells become skewed in their cytokine profile

80:227-236. and prominently express Th2-type cytokines including IL-4, -5, -6 and -13.

24. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K: Serum 41. Takai T: Fc receptors and their role in immune regulation and

levels of interleukin-6 in patients with primary head and neck autoimmunity. J Clin Immunol 2005, 25:1-18.

squamous cell carcinoma. Anticancer Res 2005, 25:2761-2765. 42. Aurora AB, Baluk P, Zhang D, Sidhu SS, Dolganov GM,

25. Terabe M, Park JM, Berzofsky JA: Role of IL-13 in regulation of Basbaum C, McDonald DM, Killeen N: Immune complex-

anti-tumor immunity and tumor growth. Cancer Immunol dependent remodeling of the airway vasculature in response

Immunother 2004, 53:79-85. to a chronic bacterial infection. J Immunol 2005, 175:6319-6326.

26. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, 43. Coussens LM, Hanahan D, Arbeit JM: Genetic predisposition

Basham B, McClanahan T, Kastelein RA, Oft M: IL-23 promotes and parameters of malignant progression in K14-HPV16

tumor incidence and growth. Nature 2006, 442:461-465. transgenic mice. Am J Pathol 1996, 149:1899-1917.

27. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R: 44. de Visser KE, Korets LV, Coussens LM: De novo carcinogenesis

Combination chemotherapy and IL-15 administration induce promoted by chronic inflammation is B lymphocyte

permanent tumor regression in a mouse lung tumor model: NK dependent. Cancer Cell 2005, 7:411-423.

and T cell-mediated effects antagonized by B cells. In HPV16 transgenic mice, combined B- and T-lymphocyte deficiency

J Immunol 1998, 161:6977-6984. attenuated innate immune cell infiltration of pre-malignant skin, leading

28. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, to decreased overall incidence of carcinoma. Adoptive transfer of

Roberts BL, St George JA, Kaplan JM: Enhanced efficacy of B-lymphocytes or serum from HPV16 mice into B- and T-lymphocyte

melanoma vaccines in the absence of B lymphocytes. deficient HPV16 mice restored chronic inflammation that is associated

J Immunother 2004, 27:273-281. with premalignant progression.

www.sciencedirect.com Current Opinion in Immunology 2007, 19:209–216


PAGINE

8

PESO

432.63 KB

PUBBLICATO

+1 anno fa


DETTAGLI
Corso di laurea: Corso di laurea magistrale in medicina e chirurgia (ordinamento U.E. - durata 6 anni) (CASERTA, NAPOLI)
SSD:

I contenuti di questa pagina costituiscono rielaborazioni personali del Publisher valeria0186 di informazioni apprese con la frequenza delle lezioni di Patologia e Fisiopatologia Generale e studio autonomo di eventuali libri di riferimento in preparazione dell'esame finale o della tesi. Non devono intendersi come materiale ufficiale dell'università Seconda Università di Napoli SUN - Unina2 o del prof Castoria Gabriella.

Acquista con carta o conto PayPal

Scarica il file tutte le volte che vuoi

Paga con un conto PayPal per usufruire della garanzia Soddisfatto o rimborsato

Recensioni
Ti è piaciuto questo appunto? Valutalo!

Altri appunti di Patologia e fisiopatologia generale

Patologia e fisiopatologia generale - Appunti
Appunto
Patologia e fisiopatologia generale - cicatrizzazione
Appunto
Patologia e fisiopatologia generale - infiammazione e tumori seconda parte
Appunto
Patologia e fisiopatologia generale - nuclear receptos in macrophages
Appunto